Kiadis Pharma receives Orphan Drug Designation for Rhitol™ from the FDA
Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol™ Orphan Drug Designation for the treatment of chronic Graft versus Host Disease (GvHD). This complication of allogeneic bone marrow transplantation is highly disabilitating and can become life threatening when the patient is unresponsive to steroid treatment. Rhitol™ has completed a multicenter phase I/II study for patients with severe steroid resistant chronic GvHD. A phase III study is anticipated to start in 2008.
“The decision by the FDA to grant Rhitol™ orphan drug designation in this area of blood cancer with unmet medical need advances our efforts to develop an innovative treatment” says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.
The FDA’s orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the United States after product approval.
About Rhitol™
Rhitol™ is under development as a treatment for patients with chronic GvHD resistant or intolerant to immunosuppressive agents. Rhitol™ treatment targets activated T cells that cause GvHD and results in immune modulation within patients with chronic GvHD, restores immune tolerance and attempts to achieve disease remission.
About chronic GvHD
GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. Graft versus Host Disease is caused by immune cells from the donor graft attacking the patient’s tissues and organs. Chronic GvHD usually develops some time after the transplantation and is generally treated by immunosuppressive drugs, such as steroids. The disease can however become life threatening when standard treatment cannot control its progression and the patient does not respond to additional immunosuppressive treatment or develops severe side effects to their use. Patients with extensive chronic GvHD have multiple organs and tissues affected and in general have a very poor quality of life.
More news
- Kiadis Pharma receives IND approval from FDA to start pivotal clinical trial with ATIR™ 8-7-2010
- Kiadis Pharma Provides ATIR™ Update: Two Year Follow-Up Data Show No Cases of Transplant Related Mortality - FDA grants ATIR™ Orphan Drug Status as a Medicinal Cell Based Therapy to Reduce Transplant Related Mortality 28-4-2010
- Kiadis Pharma announces enrollment of first patients in a multinational registration study for ATIR™ 29-11-2009
- Promising clinical data from Kiadis Pharma’s lead product ATIR™ will be presented at the 51st American Society of Hematology’s (ASH) Annual Meeting 5-11-2009
- Kiadis Pharma reports ATIR™ clinical data, further supporting its potential in mismatched bone marrow transplantations - ATIR™ data presented at the annual EBMT Presidential Symposium 8-4-2009
- Kiadis Pharma presents at the EBMT in Göteborg 31-3-2009
- Kiadis Pharma’s lead investigator presents results ATIR™ clinical trial at the BMT tandem meeting 6-2-2009
- Kiadis Pharma receives two orphan drug designations for Reviroc™ from the FDA 8-12-2008
- Kiadis Pharma announces positive clinical results for ATIR™ in mismatched bone marrow transplantations - Kiadis Pharma proceeds with pivotal trial ATIR™ 4-12-2008
- Kiadis Pharma announces continued collaboration with Professor Velardi on its lead product ATIR™ 28-11-2008
